Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients.
Rafae A, Ehsan H, Wahab A, Khan SI, Khan I, Ashraf S, Ali S, Khalid F, Neupane K, Valent J, Khouri J, Samaras C, Mazzoni S, Anwer F. Rafae A, et al. Among authors: valent j. Crit Rev Oncol Hematol. 2022 Aug;176:103744. doi: 10.1016/j.critrevonc.2022.103744. Epub 2022 Jun 15. Crit Rev Oncol Hematol. 2022. PMID: 35717005 Review.
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Bhutani D, Zonder J, Valent J, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Lum L, Ratanatharathorn V, Uberti J, Abidi MH. Bhutani D, et al. Among authors: valent j. Support Care Cancer. 2013 Sep;21(9):2437-42. doi: 10.1007/s00520-013-1808-5. Epub 2013 Apr 17. Support Care Cancer. 2013. PMID: 23591714 Free PMC article.
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenzweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZ. Usmani SZ, et al. Among authors: valent j. Blood Cancer J. 2015 Aug 7;5(8):e334. doi: 10.1038/bcj.2015.62. Blood Cancer J. 2015. PMID: 26252787 Free PMC article. No abstract available.
Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.
Hong S, Valent J, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Jagadeesh D, Hamilton BK, Hill B, Kalaycio ME, Pohlman B, Reu F, Samaras C, Sobecks R, Majhail NS, Liu HD. Hong S, et al. Among authors: valent j. Bone Marrow Transplant. 2016 May;51(5):732-4. doi: 10.1038/bmt.2015.326. Epub 2016 Jan 4. Bone Marrow Transplant. 2016. PMID: 26726941 No abstract available.
Daratumumab proves safe and highly effective in AL amyloidosis.
Khouri J, Kin A, Thapa B, Reu FJ, Bumma N, Samaras CJ, Liu HD, Karam MA, Reed J, Mathur S, Faiman BM, Devries G, Zonder J, Valent J. Khouri J, et al. Among authors: valent j. Br J Haematol. 2019 Apr;185(2):342-344. doi: 10.1111/bjh.15455. Epub 2018 Jun 25. Br J Haematol. 2019. PMID: 29938774 Free article. No abstract available.
Monoclonal gammopathy of undetermined significance: A primary care guide.
Khouri J, Samaras C, Valent J, Mejia Garcia A, Faiman B, Mathur S, Hamilton K, Nakashima M, Kalaycio M. Khouri J, et al. Among authors: valent j. Cleve Clin J Med. 2019 Jan;86(1):39-46. doi: 10.3949/ccjm.86a.17133. Cleve Clin J Med. 2019. PMID: 30624183 Free article. Review.
Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.
Anwer F, Gee KM, Iftikhar A, Baig M, Russ AD, Saeed S, Zar MA, Razzaq F, Carew J, Nawrocki S, Al-Kateb H, Cavalcante Parr NN, McBride A, Valent J, Samaras C. Anwer F, et al. Among authors: valent j. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):397-405. doi: 10.1016/j.clml.2019.03.017. Epub 2019 Mar 25. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31036508 Free PMC article. Review.
64 results